Advertisement

Topics

Priority review status granted to J&J for lower dose of Xarelto

05:04 EDT 29 Jun 2017 | SmartBrief

Johnson & Johnson unit Janssen Research & Development's supplemental new drug application for a 10-mg daily dose of Xarelto,  -More

Original Article: Priority review status granted to J&J for lower dose of Xarelto

NEXT ARTICLE

More From BioPortfolio on "Priority review status granted to J&J for lower dose of Xarelto"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...